Advertisement

Treatment of Distant and Irresectable Metastatic Disease

  • Dirk Schadendorf
  • Corinna Kochs
  • Elisabeth Livingstone
Chapter

Abstract

Patients who have distant metastatic disease (stage IV) should be discussed in interdisciplinary tumor boards with all relevant clinical partners (e.g., oncologists, surgical oncologists, radiologists, radiation oncologists, and pathologists) on a regular basis. Decisions should be based on clinical history and most recent imaging results, which should be available to all decision makers.

Keywords

Brain Metastasis Clin Oncol Metastatic Melanoma Radiation Oncol Biol Phys Cutaneous Melanoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Petersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 2007;133:104-110.Google Scholar
  2. 2.
    Leo F, Cagini L, Rocmans P, et al. Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer. 2000;83:569-572.Google Scholar
  3. 3.
    Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma: an analysis of related prognostic factors. Cancer. 1997;79:2345-2353.Google Scholar
  4. 4.
    Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000;18:3782-3793.Google Scholar
  5. 5.
    Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007;25(18 suppl):474S. Abstract 8508.Google Scholar
  6. 6.
    Ollila DW, Essner R, Wanek LA, Morton DL. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg. 1996;131:975-980.Google Scholar
  7. 7.
    Sanki A, Scolyer RA, Thompson JF. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol. 2009;35:313-319.Google Scholar
  8. 8.
    Pawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006;13:712-720.Google Scholar
  9. 9.
    Branum GD, Epstein RE, Leight GS, Seigler HF. The role of resection in the management of melanoma metastatic to the adrenal gland. Surgery. 1991;109:127-131.Google Scholar
  10. 10.
    Wornom IL 3rd, Smith JW, Soong SJ, McElvein R, Urist MM, Balch CM. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg. 1986;204:181-185.Google Scholar
  11. 11.
    Mornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 2003;13:97-103.Google Scholar
  12. 12.
    Malignes melanom: diagnostik, therapie und nachsorge. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). www.awmf.org/leitlinien/ detail/ll/032-024OL.html. Accessed June 20, 2013.
  13. 13.
    Eigentler TK, Figl A, Krex D et al; Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;117:1697-1703.Google Scholar
  14. 14.
    Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293-1300.Google Scholar
  15. 15.
    Wroński M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93:9-18.Google Scholar
  16. 16.
    Overgaard J, Gonzalez Gonzalez D, Hulshof MCCH, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. 1996. Int J Hypertherm. 2009;25:323-334.Google Scholar
  17. 17.
    Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiation Oncol Biol Phys. 1999;44:607-618.Google Scholar
  18. 18.
    Pyrhonen SO, Kajanti MJ. The use of large fractions in radiotherapy for malignant melanoma. Radiother Oncol. 1992;24:195-197.Google Scholar
  19. 19.
    Katz HR. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. Int J Radiation Oncol Biol Phys. 1981;7:907-911.Google Scholar
  20. 20.
    Herbert SH, Solin LJ, Rate WR, Hanks GE, Schultz DJ. The effect of palliative radiation therapy on epidural compression due to metastatic malignant melanoma. Cancer. 1991;67:2472-2476.Google Scholar
  21. 21.
    Dossgg LL, Memula N. The radioresponsiveness of melanoma. Int J Radiation Oncol Biol Phys. 1982;8:1131-1134.Google Scholar
  22. 22.
    Kirova YM, Chen J, Rabarijaona LI, Piedbois Y, Le Bourgeois J-P. Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res. 1999;9:611-613.Google Scholar
  23. 23.
    Rounsaville MC, Cantril ST, Fontanesi J, Vaeth JM, Green JP. Radiotherapy in the management of cutaneous melanoma: effect of time, dose, and fractionation. Front Radiat Ther Oncol. 1988;22:62-78.Google Scholar
  24. 24.
    Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiation Oncol Biol Phys. 1988;15:859-864.Google Scholar
  25. 25.
    Konefal JB, Emami B, Pilepich MV. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer. 1988;61:243-246.Google Scholar
  26. 26.
    Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiation Oncol Biol Phys. 1991;20:429-432.Google Scholar
  27. 27.
    Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011;7:208-218.Google Scholar
  28. 28.
    Bisphosphonat-assoziierte kiefernekrosen. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). www.awmf.org/leitlinien/detail/ll/007-091.html. Accessed June 20, 2013.
  29. 29.
    Caralt M, Marti J, Cortes J, et al. Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. J Hepatobiliary Pancreat Sci. 2011;18:268-275.Google Scholar
  30. 30.
    Kennedy AS, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest. 2009;27:682-690.Google Scholar
  31. 31.
    Agarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res. 2004;14:217-222.Google Scholar
  32. 32.
    Becker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2. Br J Cancer. 2002;87:840-845.Google Scholar
  33. 33.
    Peters S, Voelter V, Zografos L, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol. 2006;17:578-583.Google Scholar
  34. 34.
    Alexander HR Jr, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9:6343-6349.Google Scholar
  35. 35.
    Noter SL, Rothbarth J, Pijl MEJ, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res. 2004;14:67-72.Google Scholar
  36. 36.
    Rizell M, Mattson J, Cahlin C, Hafstrom L, Lindner P, Olausson M. Isolated hepatic perfusion for liver metastases of malignant melanoma. Melanoma Res. 2008;18:120-126.Google Scholar
  37. 37.
    van Etten B, de Wilt JH, Brunstein F, Eggermont AM, Verhoef C. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. Eur J Surg Oncol. 2009;35:539-545.Google Scholar
  38. 38.
    Navarra G. Ayav A, Weber J-C, et al. Short- and-long term results of intraoperative radiofrequency ablation of liver metastases. Int J Colorectal Dis. 2005;20:521-528.Google Scholar
  39. 39.
    Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III, eds. Holland-Frei Cancer Medicine. 5th edn. Hamilton, Ontario, Canada: BC Decker; 2000.Google Scholar
  40. 40.
    Melichar B, Voboril Z, Lojik M, Krajina A. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine. Hepatogastroenterology. 2009;56:1157-1162.Google Scholar
  41. 41.
    Vogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol. 2007;133:177-184.Google Scholar
  42. 42.
    Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.Google Scholar
  43. 43.
    Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.J Clin Oncol. 2000;18:158-166.Google Scholar
  44. 44.
    Patel PM, Suciu S, Mortier L, et al; EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011;47:1476-1483.Google Scholar
  45. 45.
    Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118-1125.Google Scholar
  46. 46.
    Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003;4:748-759.Google Scholar
  47. 47.
    Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebocontrolled study of sorafenib in combination with carboplatin and paclitaxel as secondline treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27:2823-2830.Google Scholar
  48. 48.
    Szebeni J. Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins. Curr Drug Deliv. 2005;2:443-449.Google Scholar
  49. 49.
    Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 2010;3:15-25.Google Scholar
  50. 50.
    Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010;25:601-613.Google Scholar
  51. 51.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.Google Scholar
  52. 52.
    Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.Google Scholar
  53. 53.
    Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745.Google Scholar
  54. 54.
    Yervoy [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2012.Google Scholar
  55. 55.
    Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.Google Scholar
  56. 56.
    Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park). 2009;23:488-496.Google Scholar
  57. 57.
    Andtbacka RHI, Collichio FA, Amatruda T, et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma [ASCO abstract LBA9008]. J Clin Oncol. 2013;31(suppl).Google Scholar
  58. 58.
    Biochemotherapy for the treatment of metastatic malignant melanoma. Cancer Care Ontario. www.cancercare.on.ca/pdf/pebc8-3f.pdf. Accessed June 20, 2013.
  59. 59.
    Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2005;23:9001-9007.Google Scholar
  60. 60.
    Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends Mol Med. 2012;18:27-35.Google Scholar
  61. 61.
    Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.Google Scholar
  62. 62.
    Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751.Google Scholar
  63. 63.
    Hauschild A, Grob J–J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-365.Google Scholar
  64. 64.
    Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-1703.Google Scholar
  65. 65.
    Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67:1265-1272.Google Scholar
  66. 66.
    ZELBORAF [package insert]. South San Francisco, CA: Genentech USA, Inc; 2012.Google Scholar
  67. 67.
    Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327-2334.Google Scholar
  68. 68.
    Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2904-2909.Google Scholar
  69. 69.
    Weber JS, Amin A, Minor D, Siegel J, Berman D, O’Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. 2011;21:530-534.Google Scholar
  70. 70.
    Chang J, Atkinson H, A’Hern R, Lorentzos A, Gore ME. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Eur J Cancer. 1994;30A:2093-2095.Google Scholar
  71. 71.
    Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAFmutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:1087-1095.Google Scholar
  72. 72.
    Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459-465.Google Scholar
  73. 73.
    Cashin RP, Lui P, Machado M, Hemels ME, Corey-Lisle PK, Einarson TR. Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies. Value Health. 2008;11:259-271.Google Scholar
  74. 74.
    Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest. 2003;21:821-829.Google Scholar
  75. 75.
    Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol. 2009;20(suppl 6):vi51-vi58.Google Scholar

Copyright information

© Springer Healthcare 2013

Authors and Affiliations

  • Dirk Schadendorf
    • 1
  • Corinna Kochs
    • 2
  • Elisabeth Livingstone
    • 2
  1. 1.Dermatology, Venereology and AllergologyUniversity Hospital EssenEssenGermany
  2. 2.Department for DermatologyUniversity Hospital EssenEssenGermany

Personalised recommendations